206 related articles for article (PubMed ID: 33661412)
1. Identification of anti-Epstein-Barr virus (EBV) antibody signature in EBV-associated gastric carcinoma.
Song L; Song M; Camargo MC; Van Duine J; Williams S; Chung Y; Kim KM; Lissowska J; Sivins A; Gao W; Karthikeyan K; Park J; Leja M; Cohen JI; LaBaer J; Qiu J; Rabkin CS
Gastric Cancer; 2021 Jul; 24(4):858-867. PubMed ID: 33661412
[TBL] [Abstract][Full Text] [Related]
2. Circulating Antibodies against Epstein-Barr Virus (EBV) and p53 in EBV-Positive and -Negative Gastric Cancer.
Camargo MC; Kim KM; Matsuo K; Torres J; Liao LM; Morgan D; Michel A; Waterboer T; Song M; Gulley ML; Dominguez RL; Yatabe Y; Kim S; Cortes-Martinez G; Lissowska J; Zabaleta J; Pawlita M; Rabkin CS
Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):414-419. PubMed ID: 31719065
[TBL] [Abstract][Full Text] [Related]
3. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
[TBL] [Abstract][Full Text] [Related]
4. Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan.
Coghill AE; Pfeiffer RM; Proietti C; Hsu WL; Chien YC; Lekieffre L; Krause L; Teng A; Pablo J; Yu KJ; Lou PJ; Wang CP; Liu Z; Chen CJ; Middeldorp J; Mulvenna J; Bethony J; Hildesheim A; Doolan DL
Clin Cancer Res; 2018 Mar; 24(6):1305-1314. PubMed ID: 29301829
[No Abstract] [Full Text] [Related]
5. Purified hexameric Epstein-Barr virus-encoded BARF1 protein for measuring anti-BARF1 antibody responses in nasopharyngeal carcinoma patients.
Hoebe EK; Hutajulu SH; van Beek J; Stevens SJ; Paramita DK; Greijer AE; Middeldorp JM
Clin Vaccine Immunol; 2011 Feb; 18(2):298-304. PubMed ID: 21123521
[TBL] [Abstract][Full Text] [Related]
6. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
Luo YL; Chen H; Peng SG; Lin JH; Huang PY
Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
[TBL] [Abstract][Full Text] [Related]
7. Expression of EBV antibody EA-IgA, Rta-IgG and VCA-IgA and SA in serum and the implication of combined assay in nasopharyngeal carcinoma diagnosis.
Xia C; Zhu K; Zheng G
Int J Clin Exp Pathol; 2015; 8(12):16104-10. PubMed ID: 26884888
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus antibodies and the risk of associated malignancies: review of the literature.
Coghill AE; Hildesheim A
Am J Epidemiol; 2014 Oct; 180(7):687-95. PubMed ID: 25167864
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus and human papillomavirus serum antibodies define the viral status of nasopharyngeal carcinoma in a low endemic country.
Simon J; Schroeder L; Ingarfield K; Diehl S; Werner J; Brenner N; Liu Z; Pawlita M; Pring M; Butt J; Ness A; Waterboer T
Int J Cancer; 2020 Jul; 147(2):461-471. PubMed ID: 32279316
[TBL] [Abstract][Full Text] [Related]
10. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
11. Humoral immune responses to Epstein-Barr virus encoded tumor associated proteins and their putative extracellular domains in nasopharyngeal carcinoma patients and regional controls.
Paramita DK; Fatmawati C; Juwana H; van Schaijk FG; Fachiroh J; Haryana SM; Middeldorp JM
J Med Virol; 2011 Apr; 83(4):665-78. PubMed ID: 21328382
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
Zhang WR; Du YY; Guo CY; Zhou HX; Lin JY; Meng XH; Mo HY; Luo DH
Cancer Res Treat; 2021 Oct; 53(4):991-1003. PubMed ID: 33494127
[TBL] [Abstract][Full Text] [Related]
13. Characterization of ELISA detection of broad-spectrum anti-Epstein-Barr virus antibodies associated with nasopharyngeal carcinoma.
Chang C; Middeldorp J; Yu KJ; Juwana H; Hsu WL; Lou PJ; Wang CP; Chen JY; Liu MY; Pfeiffer RM; Chen CJ; Hildesheim A
J Med Virol; 2013 Mar; 85(3):524-9. PubMed ID: 23280934
[TBL] [Abstract][Full Text] [Related]
14. [Diagnostics of nasopharyngeal carcinoma with Epstein-Barr virus (Herpesviridae, Lymphocryptovirus, HHV-4) serological and molecular markers in cases of undetected primary tumor location.].
Senyuta NB; Smirnova KV; Kondratova VN; Ignatova AV; Mudunov AM; Dushenkina TE; Liechtenstein AV; Gurtsevich VE
Vopr Virusol; 2019; 64(5):229-237. PubMed ID: 32167688
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus-specific antibodies in Epstein-Barr virus-positive and -negative gastric carcinoma cases in Japan.
Shinkura R; Yamamoto N; Koriyama C; Shinmura Y; Eizuru Y; Tokunaga M
J Med Virol; 2000 Apr; 60(4):411-6. PubMed ID: 10686024
[TBL] [Abstract][Full Text] [Related]
16. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the humoral immune response to the EBV proteome in extranodal NK/T-cell lymphoma.
Liu Z; Sarathkumara YD; Chan JKC; Kwong YL; Lam TH; Ip DKM; Chiu BC; Xu J; Su YC; Proietti C; Cooper MM; Yu KJ; Bassig B; Liang R; Hu W; Ji BT; Coghill AE; Pfeiffer RM; Hildesheim A; Rothman N; Doolan DL; Lan Q
Sci Rep; 2021 Dec; 11(1):23664. PubMed ID: 34880297
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
Guo J; Cui Z; Zheng Y; Li X; Chen Y
Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a semi-quantitative ELISA for IgA antibody against Epstein-Barr virus capsid antigen in the serological diagnosis of nasopharyngeal carcinoma.
Chen H; Chi P; Wang W; Li L; Luo Y; Fu J; Zhang L; Liu W
Int J Infect Dis; 2014 Aug; 25():110-5. PubMed ID: 24878579
[TBL] [Abstract][Full Text] [Related]
20. [Six anti-Epstein-Barr virus antibodies in healthy adults in a high risk area of nasopharyngeal carcinoma].
Yi B; Gu YL; Zong YS; Cheng WM; Ji MF
Ai Zheng; 2009 Aug; 28(8):822-6. PubMed ID: 19664327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
